Reporting - AER for non-prescription drug products (21 CFR 329.100)

Postmarketing Adverse Drug Experience Reporting

OMB: 0910-0230

IC ID: 234419

Information Collection (IC) Details

View Information Collection (IC)

Reporting - AER for non-prescription drug products (21 CFR 329.100)
 
No Modified
 
Mandatory
 
21 CFR 329.100

Document Type Form No. Form Name Instrument File URL Available Electronically? Can Be Submitted Electronically? Electronic Capability
Other-Agency Guidance 0230 Postmarketing Adverse Event Reporting for Nonprescrition Human Drug Products Marketed Without an Approved Application.PDF Yes Yes Fillable Fileable
Other-Agency Guidance 0230 Postmarketing Adverse Event Reporting for Medical Products Dietary Supplements During a Pandemic.pdf Yes Yes Fillable Fileable
Other-Agency Guidance 0230 Providing Submissions in Electronic Format—Postmarketing Safety Reports.pdf Yes Yes Fillable Fileable

Health Consumer Health and Safety

 

312 0
   
Private Sector Businesses or other for-profits
 
   100 %

  Requested Program Change Due to New Statute Program Change Due to Agency Discretion Change Due to Adjustment in Agency Estimate Change Due to Potential Violation of the PRA Previously Approved
Annual Number of Responses for this IC 19,507 0 0 -177,143 0 196,650
Annual IC Time Burden (Hours) 117,042 0 0 -1,062,858 0 1,179,900
Annual IC Cost Burden (Dollars) 5,000 0 0 5,000 0 0

Title Document Date Uploaded
No associated records found
            Blank fields in records indicate information that was not collected or not collected electronically prior to July 2006.

© 2025 OMB.report | Privacy Policy